Click here to complete the interactive survey on DMTs.
Once you submit your responses, you will be able to view all of your colleagues’ responses.

Early use of HE-DMTs
Use in pregnancy
Noteworthy studies in 2025
Switching between anti-CD20 agents

The year 2025 saw an increasing early use of high-efficacy disease-modifying therapies (HE-DMT) in patients with multiple sclerosis, either as the first-choice agent or for the first switch. The rationale for this change in practice patterns derived from the accumulating efficacy and safety data from clinical trials, database analyses and real-world studies on the use of anti-CD20 monoclonal antibodies.
Read More